The Evolving Spectrum of Human African Trypanosomiasis

• Published in: QJM : An International Journal of Medicine 2024-06, Vol.117 (6), p.391-395
• Main Author: Kennedy, Peter Ge
• Format: Article
• Language: English
• ISSN: 1460-2725; 1460-2393; 1460-2393
• DOI: 10.1093/qjmed/hcad273

Human African trypanosomiasis (HAT), or sleeping sickness, continues to be a major threat to human health in 36 countries throughout sub-Saharan Africa with up to 60 million people at risk. Over the last decade there have been several advances in this area, some of which are discussed in this overview. Due to the concerted efforts of several bodies, including better identification and treatment of cases and improved tsetse fly vector control, the number of cases of HAT has declined dramatically. The clinical heterogeneity of HAT has also been increasingly recognised and the disease, while usually fatal if untreated or inadequately treated, does not always have a uniformly fatal outcome. Improved methods of HAT diagnosis have now been developed including Rapid Diagnostic Tests (RDTs). Novel drug treatment of HAT has also been developed, notably NECT for late- stage T.b.gambiense, oral fexinidazole for early and the early component of the late-stage of T.b.gambiense, and the new oral compounds of the oxaborole group which have shown considerable promise in field trials. Advances in HAT neuropathogenesis have been steady though largely incremental, with a particular focus on the role of the BBB in parasite entry into the Central Nervous System (CNS), and the relevant importance of both innate and adaptive immunity. While the WHO goal of elimination of HAT as a public health problem by 2020 has probably been achieved, it remains to be seen whether the second more ambitious goal of interruption of transmission of HAT by 2030 will be attained.